Shahram Yazdani, MD
Cardiovascular Disease · Manassas, VANPI 1174566731
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Cardiovascular Systems Inc. at 34.4% of the total. Reporting peaked in 2019 at $16,684 and has fallen 79.5% since, to $3,425 in 2025. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 731 payments — averaging $90.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$23K
- Edwards Lifesciences$16K
- Boston Scientific$10K
- Medtronic$4K
- Abbott$3K
- Abiomed$2K
- plus $8K from 36 others
Across 79 payments — averaging $7249.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$400K
- Medtronic$114K
- AstraZeneca$25K
- Bayer$21K
- Boston Scientific$4K
- Abbott$4K
- plus $4K from 1 others
What the payments were for
- Consulting fees$10,68116%
- Speaking & faculty fees$15,48024%
- Grants$660%
- Travel & lodging$11,97118%
- Food & beverage$27,59842%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$12,478
- Coronary Orbital Atherectomy System$10,150
- Diamondback Coronary$8,388
- GENERAL - STRUCTURAL HEART$3,600
- GENERAL - THERAPIES$3,437
- Impella$1,088
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$808
- Watchman$705
- Diamondback Peripheral$657
- EVOQUE$553
- CAMZYOS$491
- CoreValve Evolut$402
- NEXLETOL$353
- Peripheral Orbital Atherectomy System$287
- FFRct$267
- SYMPLICITY G3$258
- XARELTO$250
- Repatha$246
- NEXLIZET$245
- FUROSCIX$244
How this compares
$65,817 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 212 | $250,498 |
| EntrestoSacubitril/Valsartan | 67 | $96,670 |
| JardianceEmpagliflozin | 68 | $54,458 |
| XareltoRivaroxaban | 33 | $44,573 |
| Repatha SureclickEvolocumab | 32 | $27,469 |
| FarxigaDapagliflozin Propanediol | 15 | $25,763 |
| MultaqDronedarone Hcl | 16 | $24,086 |
| LivaloPitavastatin Calcium | 13 | $7,591 |
| Metoprolol Succinate | 288 | $4,938 |
| ClopidogrelClopidogrel Bisulfate | 231 | $2,730 |
| Ranolazine ErRanolazine | 16 | $2,693 |
| Atorvastatin Calcium | 248 | $2,575 |
| Dofetilide | 11 | $2,086 |
| Rosuvastatin Calcium | 110 | $2,033 |
| Amlodipine Besylate | 234 | $1,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $294 | $250,498212 claims |
| NovartisEntresto | $484 | $96,67067 claims |
| Boehringer IngelheimJardiance | $418 | $54,45868 claims |
| Johnson & JohnsonXarelto | $577 | $44,57333 claims |
| AstraZenecaFarxiga | $351 | $25,76315 claims |
| Sanofi-aventis U.S. LLCMultaq | $121 | $24,08616 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $20 | $7,59113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Manassas
- Hamid TaheriManassas$501K
- Khalid AbousyManassas$68K
- Balbir SidhuManassas$15K
- Shahryar MafiManassas$14K
- George VetrovecRichmond$2.3M
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.